Keyphrases
Clinically Significant
100%
Clostridioides Difficile
100%
Cadazolid
100%
C.difficile Infection
100%
In Vitro Activity
100%
Intestinal Epithelial Cells
100%
Difficile
45%
Moxifloxacin
36%
Linezolid
36%
Gut Model
18%
Gut Microflora
18%
Vancomycin
18%
Resistant Isolate
18%
Metronidazole
18%
Cytotoxin
18%
Dosing Regimen
18%
Antimicrobial
18%
Viable Count
9%
Bifidobacterium
9%
Geometric Mean
9%
Ribotype 027
9%
Metronidazole Susceptibility
9%
Lactobacillus Spp
9%
Human Gut
9%
Microflora Population
9%
Titre
9%
Twice Daily
9%
Epidemic Strain
9%
Quinolones
9%
Quinolone Resistance
9%
Linezolid Resistance
9%
Resistance Emergence
9%
Total Viable Count
9%
MIC90
9%
Bacteroides Fragilis Group
9%
Linezolid-resistant
9%
Pharmacology, Toxicology and Pharmaceutical Science
Clostridium Difficile Infection
100%
Cadazolid
100%
Peptoclostridium difficile
100%
Linezolid
54%
Moxifloxacin
36%
Metronidazole
27%
Microflora
27%
Recurrent Disease
18%
Cytotoxin
18%
Vancomycin
18%
Agar
9%
Bacteroides fragilis
9%
Lactobacillus
9%
Bifidobacterium
9%
Quinolone
9%
Quinolone Derivative
9%
Antiinfective Agent
9%
Immunology and Microbiology
Peptoclostridium difficile
100%
Microflora
100%
Minimum Inhibitory Concentration
66%
Lactobacillus
33%
Viable Cell Count
33%
Agar
33%
MIC90
33%
Bacteroides fragilis
33%
Bifidobacterium
33%
Total Viable Count
33%